MeSH term
Frequency | Condition_Probility | Female | 24 | 0.0 |
Humans | 92 | 0.0 |
Pregnancy | 3 | 0.0 |
Animals | 33 | 0.0 |
Blood-Brain Barrier/physiology | 2 | 7.0 |
Drug Resistance, Multiple/genetics/physiology | 2 | 100.0 |
Hamsters | 4 | 0.0 |
Mice | 12 | 0.0 |
Pharmacogenetics | 2 | 1.0 |
Rats | 4 | 0.0 |
Species Specificity | 3 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Antineoplastic Agents/pharmacology | 4 | 0.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Genes, MDR/*genetics | 9 | 27.0 |
Research Support, Non-U.S. Gov't | 60 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 20 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
Adult | 14 | 0.0 |
DNA/genetics | 2 | 0.0 |
Genotype | 12 | 0.0 |
Male | 20 | 0.0 |
P-Glycoprotein/*genetics | 5 | 10.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Colchicine/pharmacology | 4 | 6.0 |
Drug Interactions | 7 | 0.0 |
Drug Resistance, Multiple/genetics | 3 | 6.0 |
P-Glycoprotein/genetics | 4 | 12.0 |
Transfection | 5 | 0.0 |
ATP-Binding Cassette Transporters/*metabolism | 3 | 3.0 |
*Drug Resistance, Multiple | 3 | 2.0 |
Drug Resistance, Neoplasm | 4 | 0.0 |
Models, Biological | 6 | 0.0 |
P-Glycoprotein/*metabolism | 6 | 7.0 |
Amino Acid Sequence | 5 | 0.0 |
Cell Membrane/metabolism | 8 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
P-Glycoprotein/chemistry/*metabolism | 3 | 75.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Biological Transport | 8 | 0.0 |
Drug Resistance, Multiple | 8 | 5.0 |
*Drug Resistance, Neoplasm | 6 | 3.0 |
Comparative Study | 12 | 0.0 |
DNA Primers | 4 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Drug Resistance, Multiple/*physiology | 5 | 20.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Cells, Cultured | 4 | 0.0 |
P-Glycoprotein/antagonists & inhibitors/*metabolism | 2 | 25.0 |
Swine | 2 | 0.0 |
Cell Line | 9 | 0.0 |
Cell Line, Tumor | 8 | 0.0 |
Kinetics | 3 | 0.0 |
Temperature | 2 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 2 | 1.0 |
Gene Expression Regulation/physiology | 4 | 1.0 |
Antineoplastic Agents/*pharmacology | 4 | 0.0 |
Gene Amplification | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Phenotype | 4 | 0.0 |
HL-60 Cells | 4 | 0.0 |
Multidrug Resistance-Associated Proteins | 2 | 2.0 |
Drug Resistance, Multiple/*genetics | 3 | 4.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Base Sequence | 5 | 0.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Haplotypes | 3 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Variation (Genetics) | 4 | 0.0 |
Intestines/metabolism | 2 | 1.0 |
Kidney/metabolism | 2 | 0.0 |
Liver/metabolism | 2 | 0.0 |
P-Glycoprotein/genetics/*physiology | 2 | 28.0 |
Pharmaceutical Preparations/metabolism | 2 | 6.0 |
*Pharmacokinetics | 3 | 6.0 |
Pharmacogenetics/*methods | 2 | 11.0 |
Drug Resistance, Neoplasm/genetics | 2 | 2.0 |
Aged | 8 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
*Genes, MDR | 9 | 26.0 |
Immunohistochemistry | 3 | 0.0 |
Middle Aged | 12 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Fluorouracil/*pharmacology | 2 | 5.0 |
Forecasting | 2 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
*Models, Theoretical | 2 | 3.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Predictive Value of Tests | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Stomach Neoplasms/*drug therapy/*genetics | 2 | 100.0 |
Adolescent | 3 | 0.0 |
Child | 2 | 0.0 |
Mutation | 6 | 0.0 |
*Polymorphism, Genetic | 7 | 0.0 |
Polymorphism, Single Nucleotide | 4 | 0.0 |
Liver/*metabolism | 3 | 0.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Neoplasms/*drug therapy/metabolism | 2 | 8.0 |
Gene Frequency | 4 | 0.0 |
P-Glycoprotein/genetics/metabolism | 2 | 16.0 |
ATP-Binding Cassette Transporters/genetics/*metabolism | 4 | 6.0 |
Risk Factors | 3 | 0.0 |
Alleles | 6 | 0.0 |
Cohort Studies | 3 | 0.0 |
Pharmaceutical Preparations/*metabolism | 4 | 4.0 |
Pharmacokinetics | 2 | 5.0 |
Cytochrome P-450 Enzyme System/*genetics | 3 | 0.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Immunosuppressive Agents/administration & dosage/*pharmacokinetics | 2 | 25.0 |
Tacrolimus/administration & dosage/*pharmacokinetics | 2 | 50.0 |
Adenosinetriphosphatase/metabolism | 4 | 3.0 |
Administration, Oral | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Biological Transport/genetics | 2 | 4.0 |
Colchicine/chemistry | 2 | 100.0 |
Cell Division/drug effects | 2 | 0.0 |
Hela Cells | 2 | 0.0 |
Multidrug Resistance-Associated Proteins/genetics/*metabolism | 2 | 25.0 |
P-Glycoprotein/metabolism | 7 | 11.0 |
Binding Sites | 6 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Hydrolysis | 4 | 0.0 |
NIH 3T3 Cells | 2 | 0.0 |
Photoaffinity Labels/metabolism | 3 | 30.0 |
3T3 Cells | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Multidrug Resistance-Associated Proteins/*metabolism | 3 | 20.0 |
ATP-Binding Cassette Transporters/genetics | 2 | 3.0 |
Time Factors | 6 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Substrate Specificity | 6 | 0.0 |
Homozygote | 3 | 0.0 |
Incidence | 2 | 0.0 |
Linkage Disequilibrium | 3 | 0.0 |
Heterozygote | 2 | 0.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Adenosinetriphosphatase/chemistry | 2 | 16.0 |
Catalysis | 2 | 0.0 |
P-Glycoprotein/*chemistry/metabolism | 3 | 100.0 |
Protein Conformation | 5 | 0.0 |
Verapamil/pharmacology | 3 | 3.0 |
English Abstract | 2 | 0.0 |
Calcium Channel Blockers/pharmacology | 2 | 2.0 |
Histidine/chemistry | 3 | 6.0 |
P-Glycoprotein/*chemistry | 2 | 100.0 |
Protein Binding | 6 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Cyclosporine/pharmacology | 4 | 1.0 |
Drug Resistance | 2 | 0.0 |
Area Under Curve | 2 | 0.0 |
Blood-Brain Barrier/*physiology | 2 | 5.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Multidrug Resistance-Associated Proteins/metabolism | 2 | 20.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
